Document:

EX-10.1

 Exhibit 10.1 

SETTLEMENT AGREEMENT 

This Settlement Agreement (this “Settlement Agreement”), dated as of October 4, 2017, is by and among: 

Omeros Corporation, a corporation organized and existing under the laws of Washington (“Omeros”); and 

Par Sterile Products, LLC, a Delaware limited liability company, and Par Pharmaceutical, Inc., a Delaware corporation (collectively,
“Par”). Omeros and Par are each sometimes referred to herein individually as a “Party” and are referred to collectively as the “Parties.” 

WITNESSETH: 
 WHEREAS,
Omeros is the owner of the OMIDRIA Patents, as defined below; and 
 WHEREAS, Omeros is the holder of New Drug Application (“NDA”)
No. 205388, pursuant to which it markets and sells OMIDRIA®, a pharmaceutical product containing the active ingredients phenylephrine hydrochloride and ketorolac tromethamine, in and for
the United States; and 
 WHEREAS, Omeros and Par are involved in litigation in the United States District Court for the District of
Delaware, Civil Action No. 1:15-cv-00773-RGA (the “Action”), concerning, inter alia, the validity of the OMIDRIA Patents, as well as the alleged infringement by Par of the OMIDRIA Patents resulting from Par’s requesting approval
from the United States Food and Drug Administration (the “FDA”) for the distribution and sale of the ANDA Product (as defined below) prior to expiry of the OMIDRIA Patents pursuant to Abbreviated New Drug Application (“ANDA”)
No. 208417; and 

 WHEREAS, in the Action, Omeros has asserted claims against Par; and 

WHEREAS, in the Action, Par has asserted counterclaims and defenses against Omeros challenging the validity or infringement of the OMIDRIA
Patents, and has sought a declaration of invalidity of the OMIDRIA Patents; and 
 WHEREAS, in the Action, Par has conceded, and judgment
has been entered, that the ANDA Product infringes the OMIDRIA Patents, unless they are found invalid or unenforceable; and 
 WHEREAS, the
Parties now seek to resolve the Action without further litigation. 
 NOW, THEREFORE, for good and valuable consideration, the sufficiency
and receipt of which are hereby acknowledged, the Parties intending to be legally bound do hereby agree as follows: 
 ARTICLE 1:
DEFINITIONS 
 1.1. The capitalized terms used in this Settlement Agreement shall have the meanings defined in this Article or elsewhere
in this Settlement Agreement. 
 1.2. Unless the context requires otherwise, words referred to in the singular include the plural and vice
versa, the words “include,” “includes” and “including” will be deemed to be followed by the phrase “without limitation” (unless already present), the words “herein,” “hereof” and
“hereunder,” and words of similar import, will be construed to refer to this Settlement Agreement in its entirety and not to any particular provision hereof, and the word “or” is used in the inclusive sense (and/or). 

1.3. The term “Action” shall have the meaning set forth in the preamble. 

 

  
 2 

 1.4. The term “Affiliate” shall mean, with respect to a Party, any entity or person
that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, “control” means (a) ownership, directly or through one or more
intermediaries, of (i) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (ii) more than fifty percent (50%) of the equity interests in the case
of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the board of directors or equivalent governing body of a
corporation or other entity or the right to direct the management and policies of a corporation or other entity. 
 1.5. The term
“Agencies” shall have the meaning set forth in Section 9.1. 
 1.6. The term “ANDA Product” shall mean a Generic
OMIDRIA Product sold, offered for sale or distributed pursuant to ANDA No. 208417, including supplements or amendments to ANDA No. 208417, but excluding any such supplements or amendments after the original filing date of ANDA
No. 208417 that change the mode of administration or active ingredient(s). 
 1.7. The term “Approved OMIDRIA Product” shall
mean any product sold, offered for sale or distributed pursuant to NDA No. 205388, including any supplements or amendments to NDA No. 205388, but excluding any such supplements or amendments after the original filing date of NDA
No. 205388 that change the mode of administration or active ingredient(s). 
 1.8. The term “Authorized Generic” shall mean a
pharmaceutical product that is manufactured, sold, offered for sale or distributed pursuant to NDA No. 205388 but is not sold under the trade name OMIDRIA® or another trade name or
trademark owned by Omeros or its Affiliates. 

  
 3 

 1.9. The term “District Court” shall have the meaning set forth in Section 2.1.

 1.10. The term “Effective Date” shall have the meaning set forth in Section 2.3. 

1.11. The term “Entry Date” shall have the meaning set forth in Section 5.2. 

1.12. The term “Generic OMIDRIA Product” shall mean a drug product that is sold, offered for sale or distributed under an ANDA or
application pursuant to 21 U.S.C. § 355(b)(2) that refers to the Approved OMIDRIA Product as the reference-listed drug. 
 1.13. The
term “Losses” shall mean any claim, counterclaim, demand, cause of action, suit, damages, debt, liability, obligation, right, or set-off of any and all kind or description whatsoever, including in relation to obtaining, enforcing,
challenging or defending intellectual property or rights, including costs, expenses, and attorneys’ fees related thereto or arising therefrom. 

1.14. The term “Net Sales” shall mean, with respect to any period, the actual gross amounts invoiced by Par and its Affiliates on all
of its sales to Third Parties of the ANDA Product in or for the Territory (including, but not limited to, hospital sales, mail order sales, retail sales, and sales to governmental entities, wholesalers, distributors, group purchasing organizations,
long term care facilities, and medical institutions), subject to the following enumerated points: 
  

	 	a)	“Net Sales” shall be such gross amounts less the following deductions, all as determined consistent with the customary practices in the pharmaceutical industry in the Territory, consistently applied, and
which, as applicable, are actually incurred, allowed, accrued, or specifically allocated with respect to the ANDA Product, including only: 

  
 4 

	 	(1)	normal and customary cash discounts, quantity discounts, promotional discounts, stocking or other promotional allowances; 

  

	 	(2)	sales and excise taxes, customs and any other taxes imposed on the sale, importation, use or distribution of the ANDA Product, all to the extent added to the sale price and paid and not recovered or recoverable in
accordance with applicable law (but not including taxes assessed against the income derived from such sale); 

  

	 	(3)	returns, recalls and returned goods allowances; 

  

	 	(4)	retroactive corrections (including price adjustments, including those on customer inventories following price changes) and corrections for billing errors or shipping errors; 

 

	 	(5)	chargebacks, rebates, any other similar allowances, and the portion of administrative fees, in each case, actually granted, allowed or paid to any person or entity, including group purchasing organizations, managed
health care organizations and to governments, including their agencies, or to trade customers, in each case that are not Affiliates of Par, and that are directly attributable to the sale of the ANDA Product; and 

 

	 	(6)	redistribution center (RDC) fees, information service agreement (ISA) fees, and like fees that are customary in the industry that are passed from wholesalers, retailers, distributors, and other customers back to Par.

 For the sake of clarity, all such deductions represent reductions to the gross amount invoiced for sales of the ANDA
Product by Par or its Affiliates to Third Parties in the Territory in accordance with GAAP. Net Sales shall be determined from Par’s books and records kept in accordance with GAAP, as consistently applied, subject to quarterly true-ups based on
actual deductions and credits. For clarity, the transfer of the ANDA Product by Par to one of its Affiliates shall not be considered a sale, it being understood that Net Sales by Affiliates shall be determined based upon gross invoice price of such
Product sold by such Affiliate to independent Third Parties, less the deductions set forth in this paragraph above. If the ANDA Product is bundled with other products, any discounts or other adjustments with respect to the applicable ANDA Product
shall be allocated pro rata across all products in such bundle based on the non-discounted, non-adjusted 

  
 5 

 
price for each such product. During the Royalty Term, Par shall not, and shall cause its Affiliates not to, grant or provide any rebate, discount or allowance on or with respect to the ANDA
Product that is designed or intended to encourage the purchase by Third Parties of products other than the ANDA Product, other than any rebate, discount or allowance Par or any of its Affiliates offer on a general basis and not as a loss leader for
the ANDA Product; provided that if the ANDA Product is sold with other products on a portfolio basis, no rebate, discount or allowance on or with respect to the ANDA Product shall be greater on a percentage basis in any material respect than any
rebate, discount or allowance on or with respect to any other product in such portfolio. 
  

	 	b)	“Net Sales” with respect to sales of the ANDA Product that are not made on an arm’s length basis or that are made for consideration other than cash shall be calculated based on the average per unit Net
Sales of the ANDA Product, without regard to such non-cash sales. If sales of the ANDA Product are made for consideration that includes non-cash consideration as a component, but not the entirety, of the total consideration, “Net Sales”
will be adjusted to take account of the value of the non-cash consideration component. Sales not made on an arm’s length basis will be calculated at average per unit Net Sales. 

1.15. The term “OMIDRIA Patents” shall mean United States Patent Numbers 8,173,707; 8,586,633; 9,066,856; 9,278,101; 9,399,040; and
9,486,406. 
 1.16. The term “OMIDRIA Patents Family” shall mean the OMIDRIA Patents and any United States patents issued from a
patent application that is a divisional of, continuation of, continuation-in-part of, or otherwise shares common priority with, an application from which one or more of the OMIDRIA Patents issued, or any reissue or reexamination thereof. 

1.17. The term “Omeros Releasees” shall have the meaning set forth in Section 3.2. 

1.18. The term “Par Releasees” shall have the meaning set forth in Section 3.1. 

  
 6 

 1.19. The term “Pre-Marketing” shall mean (a) communicating to potential
purchasers that Par or its Affiliates will be selling the ANDA Product in the Territory on or after the Entry Date (including, for example, notification to customers regarding the ANDA Product, and engaging customers in non-binding
pricing/contracting activities), (b) importing the ANDA Product into the Territory before the Entry Date, (c) manufacturing the ANDA Product or having the ANDA Product manufactured before the Entry Date, and (d) shipping or delivering
or distributing the ANDA Product to Third Party distributors or Affiliated distributors before the Entry Date. For the avoidance of doubt, the limited Pre-Marketing permitted pursuant to Section 5.4 shall not include entering into binding
contracts before the Entry Date for the sale of the ANDA Product to a Third Party other than a distributor, making binding offers before the Entry Date to sell the ANDA Product to a Third Party other than a distributor, or selling ANDA Product to a
Third Party other than a distributor before the Entry Date. For the further avoidance of doubt, the limited Pre-Marketing permitted pursuant to Section 5.4 shall not include the disclosure of any non-public terms of this Settlement Agreement.

 1.20. The term “Royalty Term” shall mean the period beginning on the Entry Date and ending on the date of expiration of the
last-to-expire of the OMIDRIA Patents Family. 
 1.21. The term “Signing Date” shall have the meaning set forth in
Section 2.1. 
 1.22. The term “Territory” shall mean the United States of America and its territories and possessions,
including the Commonwealth of Puerto Rico and the District of Columbia. 

  
 7 

 1.23. The term “Third Party” shall mean any entity or person that is not a Party or an
Affiliate of a Party. 
 ARTICLE 2: CONSENT JUDGMENT 

2.1. Within one (1) business day after the date of signature of the last Party to sign this Settlement Agreement (the “Signing
Date”), and earlier if possible, and subject to the confidentiality provisions of Section 10.1, counsel for the Parties shall execute a “Consent Judgment” providing for the terms of a consent judgment and stipulated dismissal of
the Action, in the form attached hereto as Exhibit A, and shall file it in the United States District Court for the District of Delaware (the “District Court”) in the Action. 

2.2. If for any reason the District Court raises an objection to the Consent Judgment as drafted or requires that the Parties modify the
Consent Judgment before it will enter it as an order of the District Court, or if after ten (10) business days the District Court has otherwise failed to enter the Consent Judgment, the Parties agree to confer promptly and in good faith in
order to take action consistent with this Settlement Agreement to secure entry of the Consent Judgment as drafted, or to agree upon modifications to the Consent Judgment, or to take such other action consistent with this Settlement Agreement to
secure entry of the Consent Judgment as drafted or with agreed-upon modifications; provided, however, that nothing contained herein shall be deemed to require a Party to agree to a modification of the Settlement Agreement or Consent Judgment that
materially affects the benefits to be obtained by, or burdens imposed upon, such Party under this Settlement Agreement as originally executed. If, after forty-five (45) calendar days have elapsed from the date on which the Consent Judgment was
filed, such efforts have failed to secure entry of the Consent Judgment as originally filed or with agreed-upon modifications, notwithstanding anything herein to the contrary, this Settlement Agreement shall be null and void and have no further
legal effect, save for Article 10 , which shall continue in full force and effect. 
  

  
 8 

 2.3. The date on which the Consent Judgment is entered by the District Court, whether with or
without modification as provided for in Section 2.2, shall be the “Effective Date” of this Settlement Agreement. Notwithstanding anything herein to the contrary, the provisions of Articles 1, 2, 8, 9 and 10 shall become effective upon
the Signing Date. 
 ARTICLE 3: MUTUAL RELEASES 

3.1. In settlement of the disputed claims in the Action, and in consideration of the representations, warranties and covenants contained in
this Settlement Agreement, subject to and effective only upon entry of the Consent Judgment (whether with or without modification as provided for in Section 2.2), Omeros, on behalf of itself and its Affiliates, and its and their respective
predecessors, successors, assigns, agents, officers, directors, employees and representatives, hereby fully, finally and irrevocably relinquishes, releases and discharges Par and its Affiliates, and its and their respective predecessors, successors,
assigns, agents, officers, directors, employees, representatives, suppliers, importers, manufacturers, distributors and customers (the “Par Releasees”), from any and all claims, demands, damages, liabilities, obligations, and causes of
action known or unknown, suspected or unsuspected, in law or equity, including costs, expenses and attorneys’ fees, that were asserted, or that could have been asserted, by Omeros or any of its Affiliates in connection with the ANDA Product,
the Approved OMIDRIA Product or the Action and arising before the Effective Date of this Settlement Agreement. For the avoidance of doubt, the release granted under this Section 3.1 shall not apply to any finished product aside from the ANDA
Product, or to the supply of ingredients for any finished product aside from the ANDA Product. 

  
 9 

 3.2. In settlement of the disputed claims in the Action, and in consideration of the
representations, warranties and covenants contained in this Settlement Agreement, subject to and effective only upon entry of the Consent Judgment (whether with or without modification as provided for in Section 2.2), Par, on behalf of itself
and its Affiliates, and its and their respective predecessors, successors, assigns, agents, officers, directors, employees and representatives, hereby fully, finally and irrevocably relinquishes, releases and discharges Omeros and its Affiliates,
and its and their respective predecessors, successors, assigns, agents, officers, directors, employees, representatives, suppliers, importers, manufacturers, distributors and customers (the “Omeros Releasees”), from any and all claims,
demands, damages, liabilities, obligations, and causes of action known or unknown, suspected or unsuspected, in law or equity, including costs, expenses and attorneys’ fees, that were asserted, or that could have been asserted, by Par or any of
its Affiliates in connection with the ANDA Product, the Approved OMIDRIA Product or the Action and arising before the Effective Date of this Settlement Agreement. 

3.3. In connection with this Settlement Agreement, the Parties and all of their respective Affiliates expressly waive and relinquish all rights
and benefits afforded by Section 1542 of the California Civil Code, which provides as follows: 
 A GENERAL RELEASE DOES NOT EXTEND TO
CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN TO HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 

  
 10 

 Further, the Parties and all of their respective Affiliates expressly waive and relinquish all
rights and benefits afforded by any law in any other jurisdiction similar to Section 1542 of the California Civil Code. 
 3.4. For the
avoidance of doubt, the releases set forth in this Article 3 do not apply to actions to enforce any requirements or provisions of this Settlement Agreement, including, but not limited to, the provisions of the Consent Judgment. 

ARTICLE 4: PATENT VALIDITY AND INFRINGEMENT 

4.1. Par, for itself and its Affiliates, acknowledges and agrees that the OMIDRIA Patents are valid and enforceable and would be infringed by
the manufacture, use, sale, offer to sell, importation or distribution of the ANDA Product in or for the Territory prior to the Entry Date. 

4.2. Par, for itself and its Affiliates, agrees not to challenge or otherwise dispute or contest, and not to assist others, whether directly or
indirectly, or join in any action, challenging or otherwise disputing or contesting, in any litigation or proceeding (a) the validity, enforceability, or patentability of any patent in the OMIDRIA Patents Family, or (b) the infringement of
any patent in the OMIDRIA Patents Family by the manufacture, use, sale, offer to sell, importation or distribution of a Generic OMIDRIA Product, in each case ((a) and (b)) in any court or administrative agency (including without limitation the
United States Patent and Trademark Office) having jurisdiction to consider the issue, except as may be required pursuant to compulsory legal process in litigation or other proceeding initiated by a Third Party without assistance by Par or its
Affiliates. Without limiting the generality of the foregoing, Par shall instruct the attorneys and experts engaged by or on behalf of Par in connection with the Action not to use or transfer to any Third Party any confidential information of Omeros
or its Affiliates or any work product or other materials generated in 

  
 11 

 
connection with the Action, unless such disclosure is compelled by law. Notwithstanding the foregoing, Par shall not be precluded from challenging in court the validity, enforceability or
infringement of any patent in the OMIDRIA Patents Family in an action that does not involve or have as its basis, cause, or predicate any or all of the following: (i) the ANDA Product, (ii) the Approved OMIDRIA Product, and (iii) a
Generic OMIDRIA Product. 
 4.3. Par, on behalf of itself and its Affiliates, agrees not to seek, directly or indirectly (including, for
clarity, by or through its attorneys or agents or through or by assisting any Third Party, whether directly or indirectly), reexamination, inter partes review or any other post-grant review of any patent in the OMIDRIA Patents Family.
Notwithstanding the foregoing Sections 4.2 and 4.3, in the event that (a) Par has filed with FDA a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) as to a patent in the OMIDRIA Patent Family with respect to a Par product other than
the ANDA Product or any Generic OMIDRIA Product and (b) Omeros affirmatively asserts a patent claim of such patent against Par in a future action with respect to such Par product, Par shall not be precluded from challenging the patentability of
such claim at the U.S. Patent and Trademark Office. For clarity, Par shall not be permitted to challenge any patent claim that Omeros has not asserted in such future action as described in clause (b) in the preceding sentence. 

ARTICLE 5: LICENSE 
 5.1.
Omeros, for itself and its Affiliates, hereby grants Par and its Affiliates, on and from the Entry Date through the expiration of the last-to-expire of the OMIDRIA Patents Family, a royalty-bearing (in accordance with Section 7.1),
non-exclusive, non-sublicensable, non-transferable (except as expressly permitted by Section 10.3) right and license under their respective rights in and to the OMIDRIA Patents Family to make, have made, use, sell, offer to sell, import, and
distribute the ANDA Product in or for the Territory. 

  
 12 

 
For the avoidance of doubt, the right and license granted under this Section 5.1 shall not apply to the manufacture or distribution of the ANDA Product for sale to Third Parties for use or
consumption outside the Territory. For the further avoidance of doubt, the right and license granted under this Section 5.1 shall not apply to the manufacture or distribution of any finished product aside from the ANDA Product, or to the supply
of ingredients for any finished product aside from the ANDA Product. 
 5.2. For the purposes of this Settlement Agreement, the “Entry
Date” shall mean the earliest of (a) April 1, 2032, (b) the date of a final court decision from which no appeal has been or can be taken (other than a petition to the U.S. Supreme Court for a writ of certiorari) holding that all
claims of the OMIDRIA Patents asserted by Omeros and adjudicated at the time of such final court decision are invalid or unenforceable, (c) the date prior to April 1, 2032 on which any Third Party generic manufacturer launches a Generic
OMIDRIA Product in the Territory under a license or other agreement with Omeros or any of its Affiliates, and (d) the date prior to April 1, 2032 on which Omeros or any of its Affiliates or a Third Party launches an Authorized Generic
under a license or other agreement with Omeros or its Affiliates. 
 5.3. Nothing in these grants to Par or its Affiliates or otherwise
contained in this Settlement Agreement shall give rise to an express or implied license under any patent other than the OMIDRIA Patents Family. 

5.4. Notwithstanding any of the provisions of Articles 5 and 8, Par and its Affiliates may engage in (i) the Pre-Marketing activities
contemplated under clauses (b), (c) and (d) of Section 1.19 from the date that is six (6) months in advance of the Entry Date and (ii) the Pre-Marketing activities contemplated under clause (a) of Section 1.19 from
the date that is twenty one (21) days in advance of the Entry Date. Except as provided in the immediately preceding sentence, Par and its Affiliates may not engage in any of the Pre-Marketing activities contemplated under Section 1.19
prior to the Entry Date. 

  
 13 

 ARTICLE 6: COVENANTS 

6.1. Par, for itself and its Affiliates, hereby covenants as of the Effective Date of this Settlement Agreement and thereafter during the time
that this Settlement Agreement is in effect: 
  

	 	a)	Not to sue, not to assign to any other entity a right to sue, and not to authorize any other entity to sue, any Omeros Releasee for Losses, known or unknown, suspected or unsuspected, in law or equity, that were
asserted or that could have been asserted by Par in connection with ANDA No. 208417, the ANDA Product, an Approved OMIDRIA Product or the Action and arising before the Effective Date of this Settlement Agreement; and 

 

	 	b)	Unless otherwise permitted under this Settlement Agreement, that neither Par nor its Affiliates will, directly or indirectly, (i) at any time beginning with the Effective Date of this Settlement Agreement and
ending at 12:01 a.m. on the Entry Date, (A) use, sell, offer to sell, import or distribute in or into the Territory or (B) make or have made in the Territory or (ii) at any time beginning with the Effective Date of this Settlement
Agreement and ending at 12:01 a.m. on the Entry Date, authorize, assist or materially encourage others to (A) use, sell, offer to sell, import or distribute in or into the Territory or (B) make or have made in the Territory or indemnify
others regarding or participate in the profits of others arising from, or otherwise receive consideration with respect to, the sale in or into the Territory of, in the case of both clauses (i) and (ii), the ANDA Product or any other Generic
OMIDRIA Product; and 

  

	 	c)	Not to sue, not to assign to any other entity a right to sue, and not to authorize, assist or materially encourage any other entity to sue, any Omeros Releasee for any claim, counterclaim, demand, cause of action, suit,
damages, debt, liability, obligation, right, or set-off of any and all kind or description whatsoever arising out of the sale of the ANDA Product in or into the Territory; and 

 

	 	d)	Not to encourage, induce or otherwise facilitate any Third Party to take any action that would be a breach of this Settlement Agreement if engaged in by Par or its Affiliates (including, for clarity, seeking
reexamination, inter partes review or any other post-grant review of any patent in the OMIDRIA Patents Family, other than as expressly permitted by Section 4.3). 

 

  
 14 

 6.2. Omeros, for itself and its Affiliates, hereby covenants as of the Effective Date of this
Settlement Agreement and thereafter during the time that this Settlement Agreement is in effect: 
  

	 	a)	Not to sue, not to assign to any other entity a right to sue, and not to authorize, assist or materially encourage any other entity to sue, any Par Releasee or their suppliers, distributors, or customers (including
doctors and patients) for Losses, known or unknown, suspected or unsuspected, in law or equity, that were asserted or that could have been asserted by Omeros in connection with ANDA No. 208417, the ANDA Product, an Approved OMIDRIA Product or
the Action and arising before the Effective Date of this Settlement Agreement; and 

  

	 	b)	Not to assert any patent remedies to which they would be entitled under 35 U.S.C. § 271(e)(4) or any other U.S. patent law (i) if the District Court had found that Par’s filing of ANDA No. 208417
infringed the OMIDRIA Patents or any United States patents or patent applications owned, in-licensed or otherwise controlled by, now or in the future, Omeros or any of their Affiliates or (ii) with respect to the sale of the ANDA Product on or
after the Entry Date; and 

  

	 	c)	Unless required for purposes of public policy or safety, not to take any action (except for conventional commercial activities) and not to authorize, assist or materially encourage any other entity to take any action,
to prevent or delay the approval, launch, manufacture, use, sale, offer for sale, importation or distribution of the ANDA Product in or for the Territory as permitted under the terms of this Settlement Agreement; and 

 

	 	d)	Upon Par’s written request, to provide the FDA with written confirmation of the Entry Date and the licenses, covenants and waivers herein; and 

 

	 	e)	 (i) Not to sue, not to assign to any other entity a right to sue, and not to authorize, assist or materially
encourage any other entity to sue, any Par Releasee or any of their manufacturers, suppliers, distributors, or customers (including doctors and patients) for any Losses asserting that the manufacture, use, sale, offer for sale,

  
 15 

	 	
importation or distribution of the ANDA Product in or for the Territory, during the period that the license grant in Section 5.1 is in effect, infringes any United States patents or patent
applications owned, in-licensed or otherwise controlled by, now or in the future, Omeros or any of their Affiliates and (ii) to impose the foregoing covenant not to sue on any Third Party to which it or any of its Affiliates may assign or
otherwise transfer, or license or sublicense, any such patent rights. For the avoidance of doubt, the immediately foregoing covenant not to sue shall not apply to the manufacture or distribution of the ANDA Product for sale to Third Parties for use
or consumption outside the Territory. 

 ARTICLE 7: ROYALTIES; RECORD-KEEPING; AUDIT 

7.1. In consideration of the license granted under Article 5, Par shall pay to Omeros running royalties in an amount equal to fifteen percent
(15%) of Net Sales of the ANDA Product during the Royalty Term. Par shall pay such royalties in accordance with Section 7.1. 

7.2. Not later than forty five (45) days after the end of each calendar quarter, commencing on the Entry Date and continuing through the
end of the Royalty Term, Par shall: 
  

	 	a)	Deliver to Omeros a written report, in such form as the Parties mutually agree, that contains the information specified in Exhibit B with respect to the prior calendar quarter; and 

 

	 	b)	Pay to Omeros, by wire transfer to an account designated in writing by Omeros, the amount owed to Omeros with respect to such calendar quarter as determined in accordance with Section 7.1. 

7.3. Par shall maintain, and shall cause its Affiliates to maintain, complete and accurate books and records in such detail as is necessary to
accurately calculate the amounts payable to Omeros under Section 7.1. Such books and records shall be maintained for a period of at least twelve (12) months after the end of the Royalty Term. Once during each calendar year of the Royalty
Term, and on no less than thirty (30) days’ written notice to 

  
 16 

 
Par, Omeros shall have the right to have an independent accounting firm reasonably acceptable to Par audit and examine the relevant books and records as may be reasonably necessary to determine
or verify the amount of payments due hereunder and Par’s compliance with its obligations hereunder. Such audit and examination shall be conducted and shall take place, and Par shall, and shall cause its Affiliates to, make such books and
records available, during normal business hours at a facility in the United States. The audit shall be conducted expeditiously and within the time reasonably necessary to accomplish the purposes of the audit. Before permitting such independent
accounting firm to have access to such books and records, Par may require such independent accounting firm and its personnel involved in such audit to sign a customary confidentiality agreement in form and substance reasonably acceptable to Par as
to any information subject to confidential treatment under Section 10.1 which is to be provided to such accounting firm or to which such accounting firm will have access while conducting the audit under this Section 7.3. The independent
accounting firm will prepare and provide to the Parties a written report stating whether the reports submitted and amounts paid pursuant to this Article 7 were correct or incorrect, and the amounts of any discrepancies. In the event that there was
an underpayment or overpayment by Par hereunder, Par or Omeros, as the case may be, shall promptly (but in no event later than thirty (30) days after receipt of the independent accountant’s report so concluding) make payment to the other
of the amount of such underpayment or overpayment. Omeros shall bear the costs and expenses of such audit, unless the audit finds a discrepancy of ten percent (10%) or more between Par’s payment obligations and payments for any audited
period, in which case Par shall bear the cost of such audit. 

  
 17 

 7.4. Omeros shall be responsible for and shall pay all taxes payable on any income or any
payments by Par to Omeros. Par and Omeros shall bear sole responsibility for payment of compensation to their respective personnel, employees, or subcontractors and for all employment taxes and withholding with respect to such compensation pursuant
to applicable law. All payments made by Par to Omeros under this Settlement Agreement shall be made without any deduction or withholding for, or on account of, any tax, except that Par shall have the right to withhold taxes on income or income
equivalents in the event that the revenue authorities in any country require the withholding of taxes on amounts paid hereunder to Omeros. Par shall secure and promptly send to Omeros proof of such taxes, duties, or other levies withheld and paid by
Par for the benefit of Omeros. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to time in effect. 

7.5. All amounts payable by Par hereunder shall be paid in U.S. dollars. 

7.6. Any payment under this Settlement Agreement that is not made when due shall bear interest on such past due amount from the date such
amount became past due until the date payment is actually made at a rate equal to the greater of (a) three percent (3%) per annum above “Prime” as defined in the print edition of The Wall Street Journal, Eastern Edition, on the
payment due date or, if unavailable, on the latest date prior to the payment due date on which such rate is available and (b) twelve percent (12%) per annum, but in any event not to exceed the maximum rate allowed by law, calculated on a
daily basis on the actual number of days elapsed from the payment due date to the date of actual payment. 
  

  
 18 

 ARTICLE 8: REPRESENTATIONS AND WARRANTIES 

8.1. Each Party represents and warrants to the other Party that: 
  

	 	a)	It has the corporate, partnership or limited liability company power and authority to enter into this Settlement Agreement and to perform its obligations hereunder; and 

 

	 	b)	The execution, delivery and performance of this Settlement Agreement have been duly authorized by all necessary corporate or other organizational actions of the Party and its Affiliates; and 

 

	 	c)	The execution and delivery of this Settlement Agreement and the performance by the Party of any of its obligations hereunder do not and will not conflict with or result in a breach of any other agreement to which it or
any of its Affiliates is a party, any judgment of any court or governmental body applicable to the Party or its properties, or, to the Party’s knowledge, any statute, decree, order, rule or regulation of any court or governmental authority
applicable to the Party or its properties; and 

  

	 	d)	Upon execution and delivery of this Settlement Agreement by both Parties, this Settlement Agreement is a valid obligation binding upon such Party and enforceable in accordance with its terms except as enforceability may
be limited in future bankruptcy or insolvency. 

 8.2. Par, on behalf of itself and its Affiliates, represents and warrants to
Omeros that, as of the Signing Date and the Effective Date of this Settlement Agreement, Par and its Affiliates own all right, title and interest in and to ANDA No. 208417, no other person or entity has any rights under ANDA No. 208417,
and neither Par nor any of its Affiliates has transferred or assigned any of their rights under ANDA No. 208417 to any party. 
 8.3.
Par further represents and warrants to Omeros that, as of the Signing Date and the Effective Date of this Settlement Agreement, neither Par nor its Affiliates have discussed with any Third Party any aspect of the negotiations of this Settlement
Agreement or the Consent Judgment or any of the terms or conditions hereof or thereof. 
 8.4. No Party makes any express or implied
warranties that any product or process can be made, used, sold, offered for sale, imported or distributed without infringing intellectual property rights owned or controlled by Third Parties. 

  
 19 

 8.5. Omeros, on behalf of itself and its Affiliates, further represents and warrants to Par that
they collectively or individually or through one or more Affiliates own all right, title and interest in and to the OMIDRIA Patents, and neither they nor their Affiliates have transferred or assigned any of their rights under the OMIDRIA Patents to
any Third Party. 
 ARTICLE 9: NOTIFICATION OF SETTLEMENT AGREEMENT 

TO THE FEDERAL TRADE COMMISSION AND DEPARTMENT OF JUSTICE 

9.1. Within ten (10) business days following the Signing Date, the Parties shall comply with the requirements of Title XI, Subtitle B of
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, by filing or causing to be filed all necessary documents with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department
of Justice (collectively the “Agencies”). 
 9.2. The Parties shall use commercially reasonable efforts to coordinate the foregoing
filings and any responses thereto, to make such filings promptly and to respond promptly to any requests for additional information made by either of the Agencies, and to coordinate any necessary or desirable joint presentations. Each Party reserves
the right to communicate with the Agencies regarding such filings as it believes appropriate. Each Party shall keep the other informed of such communications (unless otherwise directed by either of the Agencies) and shall not disclose any
confidential information of the other Party without that Party’s consent, which shall not be unreasonably withheld. 

  
 20 

 ARTICLE 10: GENERAL PROVISIONS 

10.1. Confidentiality. Either Party may issue a press release with respect to this Settlement Agreement, the timing, content and form
of which shall be determined by such Party in its sole discretion. Except as expressly provided in the immediately preceding sentence or as required by statute, ordinance, regulation, or compulsory legal process, neither the Parties nor their
Affiliates shall publicly announce or otherwise disclose to Third Parties any of the confidential terms of this Settlement Agreement without the prior written approval of the other Party. Each Party acknowledges that, if the stock of the other Party
is publicly traded, the other publicly traded Party will be required to publicly disclose certain terms of this Settlement Agreement in filings with the United States Securities and Exchange Commission (“SEC”) and will be required to
include a copy of this Settlement Agreement in filings with the SEC, and, to the extent that the other publicly traded Party determines that such disclosures are required, notwithstanding the provisions of this Section 10.1, each Party consents
to the other publicly traded Party’s disclosure of such terms of this Settlement Agreement in SEC filings and the inclusion of a copy of this Settlement Agreement in filings with the SEC, with the timing, form and content of each as determined
by the other publicly traded Party in its sole discretion. Notwithstanding anything to the contrary above, (i) Omeros may disclose the terms of this Settlement Agreement to Third Parties in connection with patent litigation involving the
Approved OMIDRIA Product or in connection with settlement discussions and agreements related to or involving the Approved OMIDRIA Product, subject to such Third Parties undertaking to keep the terms of this Settlement Agreement strictly confidential
in accordance with confidentiality terms at least as restrictive as the terms hereof, (ii) Par may disclose such terms of this Settlement Agreement to the FDA as may be necessary in obtaining and maintaining FDA approval of its ANDA
No. 208417, so long as Par requests that the FDA maintain such terms in confidence, and (iii) each Party may disclose the terms of this Settlement Agreement to its respective Affiliates, and its and their respective insurers, lenders,
shareholders and prospective investors, attorneys, accountants, 

  
 21 

 and prospective and actual acquirers, subject to such Affiliates, insurers, lenders, shareholders and prospective
investors, attorneys, accountants and prospective and actual acquirers undertaking to keep the terms of this Settlement Agreement strictly confidential in accordance with confidentiality terms at least as restrictive as the terms hereof. 

10.2. Indemnification. Par and its Affiliates shall indemnify, defend, and hold harmless Omeros and its Affiliates, and its and their
respective officers, directors, shareholders, employees, agents, representatives, successors and assigns, heirs, administrators, executors, suppliers, and manufacturers from any claims, losses, liabilities, costs and expenses (including reasonable
attorneys’ fees) arising solely out of the manufacture, use, sale, offer to sell, importation, and distribution of the ANDA Product and which relate to an aspect of the ANDA Product for which Par is the proximate cause, including damages
related to personal injury of any Third Party arising out of any product liability claim made by such Third Party. 
 10.3.
Assignment. This Settlement Agreement, including the obligations of the Parties under the Consent Judgment, shall be binding upon and shall inure to the benefit of each Party hereto, and each of its Affiliates, successors and permitted
assigns, and any Third Party to which any rights are transferred under ANDA No. 208417 or the ANDA Product. Except as otherwise provided herein, none of Omeros and Par shall have the power to assign or otherwise transfer this Settlement
Agreement or any interest herein or right hereunder without the prior written consent of the other Party, and any such purported assignment, transfer or attempt to assign or transfer any interest herein or right hereunder without such consent shall
be void and of no effect. Notwithstanding the foregoing, either Party may, upon written notice to the other Party but without obtaining the other Party’s consent, assign its 

  
 22 

 
rights and obligations under this Settlement Agreement to any of its Affiliates, to any lender providing financing to that Party or its Affiliates for collateral security purposes, or to any
successor in interest to that Party’s entire business or to its Approved OMIDRIA Product or Generic OMIDRIA Product business, as the case may be, provided that (a) notwithstanding any such assignment, such Party shall remain liable for its
and its Affiliates’ performance under this Settlement Agreement; (b) no such assignment shall in any manner limit or impair the obligations of that Party hereunder; (c) no such assignment shall in any manner limit or impair the
benefits provided to Omeros under Section 3.2, Section 4.2, Section 4.3 or Section 6.1 or provided to Par under Section 3.1 or Section 6.2; and (d) following a transfer by a Party to its Affiliate, any subsequent
transaction that would cause such Affiliate to cease to be an Affiliate of such Party shall be deemed to be an assignment of this Settlement Agreement subject to this Section 10.3. 

10.4. Governing Law. This Settlement Agreement and the rights and obligations of the Parties under this Settlement Agreement shall be
governed and construed in accordance with the laws of the State of Delaware, without regard to its choice-of-law or conflicts-of-law principles that might otherwise refer construction or interpretation of this Settlement Agreement to the substantive
law of another jurisdiction. The Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of Delaware for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this
Settlement Agreement and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. 

  
 23 

 10.5. Relief in the Event of Breach. Par, for itself and its Affiliates, acknowledges and
agrees that the restrictions set forth herein on the manufacture, use, sale, offer to sell, importation and distribution of the ANDA Product are reasonable and necessary to protect the legitimate interests of Omeros, that Omeros would not have
entered into this Settlement Agreement in the absence of such restrictions, and that any breach of those restrictions will result in irreparable injury to Omeros for which there will be no adequate remedy at law. Accordingly, if Par engages in a
breach of any of its undertakings in Section 4.2, Section 4.3 or Section 6.1 of this Settlement Agreement, in addition to any other remedy Omeros may have at law or in equity, Par agrees, that, upon a determination by a court of such
breach, Omeros shall be entitled to a preliminary injunction to prevent the continuance of such breach, and Par agrees that Omeros will not be required to demonstrate that the balance of hardships supports the entry of injunctive relief in order to
obtain such relief. Further, in the event that Par is finally determined by a court to have engaged in a breach of its undertakings in Article 4 or Section 6.1 of this Settlement Agreement, Omeros reserves, and Par and its Affiliates shall not
contest, Omeros’s right to seek damages and any other remedies for patent infringement to the full extent of the law (although Par may contest the quantum of damages or scope of other remedies). 

10.6. Waiver. No waiver of a breach, failure of any condition, or any right or remedy, contained in or granted by the provisions of this
Settlement Agreement shall be effective unless it is in writing and signed by the Party waiving the breach, failure, right or remedy. No waiver of any breach, failure, right or remedy shall be deemed a waiver of any other breach, failure, right or
remedy, whether or not similar, nor shall any waiver constitute a continuing waiver unless the writing so specifies. 
 10.7. Legal
Advice. Each Party and its counsel have participated fully in the review and revision of this Settlement Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not apply in
interpreting this Settlement Agreement. 
  

  
 24 

 10.8. Enforceability. If a court of competent jurisdiction holds any provision of this
Settlement Agreement to be illegal, unenforceable, or invalid, in whole or in part for any reason, the Parties agree to use commercially reasonable efforts to negotiate a provision, in replacement of the provision held illegal, unenforceable, or
invalid, that is consistent with applicable law and accomplishes, as nearly as possible, the original intention of the Parties with respect thereto. 

10.9. Admissibility. In the event that there is no Effective Date of this Settlement Agreement or the Consent Judgment is vacated,
(a) neither the provisions of this Settlement Agreement, nor the Settlement Agreement itself (except the provisions hereof that remain in effect), may be offered into evidence, or be referred to in any testimonial or other evidence, by any
Party or any of their Affiliates at any trial, action or other proceeding pertaining to the subject matter hereof, and (b) nothing herein shall be construed as an admission or waiver by any Party or any of their Affiliates as to any factual or
legal matter; provided, however, that this Section 10.9 shall not apply in any actions to enforce any requirements or provisions of this Settlement Agreement or the Consent Judgment. 

10.10. Entire Agreement. This Settlement Agreement and the Exhibit represents the entire understanding and agreement of the Parties with
regard to the matters addressed herein. 
 10.11. Modification. No terms or conditions of this Settlement Agreement will be varied or
modified by any prior or subsequent statement, conduct or act of either Party, except that the Parties may supplement, amend, or modify this Settlement Agreement by a subsequent written agreement executed by the Parties through their authorized
representatives. 
  

  
 25 

 10.12. Counterparts. This Settlement Agreement may be executed in any number of
counterparts, and through pdf, facsimile or photocopy signatures. Each counterpart shall be deemed an original instrument, but all counterparts together shall constitute but one agreement. 

10.13. Limitation of Rights Granted. Except for the rights, agreements and covenants specifically granted pursuant to this Settlement
Agreement, no other rights, agreements or covenants are granted or implied by this Settlement Agreement. Par shall have no right, title or interest in or to (a) any trademark, trade dress, brand mark, service mark, trade name, brand name, logo
or other similar business symbol of Omeros or its Affiliates, including the trademark OMIDRIA® or any trade dress of any OMIDRIA®
product or (b) any know-how, trade secrets, copyrights or other intellectual property of Omeros or its Affiliates, except the limited rights expressly provided for herein. 

10.14. Notices: All notices, requests, demands, or other communications under this Settlement Agreement shall be in writing. Notice
shall be sufficiently given (and shall be deemed to be duly given upon receipt) by delivery in person, by facsimile or by overnight delivery service maintaining records of receipt to the respective Parties at the addresses specified below, or in
each case such other address as such Party may hereafter specify by notice to the other Party. 
 Addresses for purpose of giving notice are
as follows: 

  
 26 

 If to Omeros: 

Omeros Corporation 
 201 Elliott
Avenue West 
 Seattle, WA 98119 

Attn.: Chief Executive Officer 

With a copy to: 
 Omeros
Corporation 
 201 Elliott Avenue West 

Seattle, WA 98119 
 Attn.: General
Counsel 
 If to Par: 
 Par
Pharmaceutical, Inc. 
 1 Ram Ridge Road 

Chestnut Ridge, NY 10977 
 Attn:
General Counsel 
 Fax: (845) 573-5600 

With a copy to: 
 David
Silverstein 
 Axinn, Veltrop & Harkrider LLP 

950 F Street, NW 7th Floor 

Washington, DC 20004 
 Fax:
(212) 728-2201 
 [Signature Page Follows] 

  
 27 

 IN WITNESS WHEREOF, the Parties, through their authorized officers, have executed this Settlement
Agreement as of the Signing Date. 
  

									
	Omeros Corporation	 		  	Par Sterile Products, LLC
					
	By:	 	 /s/ Gregory A. Demopulos, M.D.
	 		  	By:	  	 /s/ Lawrence M. Brown

	Name:	 	Gregory A. Demopulos, M.D.	 		  	Name:	  	Lawrence M. Brown
	Title:	 	Chairman and CEO	 		  	Title:	  	Vice President, Legal
	Date:	 	4 October 2017	 		  	Date:	  	10/4/17
				
		 		 		  	Par Pharmaceutical, Inc.
					
		 		 		  	By:	  	 /s/ Lawrence M. Brown

		 		 		  	Name:	  	Lawrence M. Brown
		 		 		  	Title:	  	Vice President, Legal
		 		 		  	Date:	  	10/4/17

 EXHIBIT A: CONSENT JUDGMENT 

IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF DELAWARE 
  

					
	  
  
	 	X	  	
	OMEROS CORPORATION,	 	:	  	
		 	:	  	
	                                Plaintiff,	 	:	  	
		 	:	  	
	                    v.	 	:	  	Civil Action No. 1:15-cv-00773-RGA
		 	:	  	
	PAR STERILE PRODUCTS, LLC,	 	:	  	
	and	 	:	  	
	PAR PHARMACEUTICAL, INC.,	 	:	  	
		 	:	  	
	                                Defendants.	 	:	  	
	  
  
	 	X	  	

 CONSENT JUDGMENT 

Plaintiffs Omeros Corporation (hereinafter “Omeros”), and Defendants Par Sterile Products, LLC and Par Pharmaceutical, Inc.
(hereinafter collectively “Par”), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of this action and have set forth those terms and conditions in a Settlement Agreement
(the “Settlement Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this action as follows: 

IT IS this             day of
            , 2017: 
 ORDERED, ADJUDGED AND DECREED as follows: 

1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties. 

2. As used in this Consent Judgment, (i) the term “ANDA Product” shall mean a drug product sold, offered for sale or distributed
pursuant to Abbreviated New Drug Application No. 208417 (and defined in greater detail in the Settlement Agreement); the term 

 
“OMIDRIA Patents” shall mean United States Patent Numbers 8,173,707, 8,586,633, 9,066,856, 9,278,101, 9,399,040, and 9,486,406, and (iii) the term “Affiliate” shall mean
any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Par; for purposes of this definition, “control” means (a) ownership, directly or through
one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in
the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a
corporation or other entity or the right to direct the management and policies of a corporation or other entity. 
 3. Unless otherwise
specifically authorized pursuant to the Settlement Agreement, Par, including any of its Affiliates, successors and assigns, is enjoined until April 1, 2032 from infringing the OMIDRIA Patents, on its own part or through any Affiliate, by
making, having made, using, selling, offering to sell, importing or distributing the ANDA Product. 
 4. Compliance with this Consent
Judgment may be enforced by Omeros and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement. 
 5.
This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement. 
 6. All
claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys’ fees to any party. 

 

	
	  
 Richard G. Andrews,
U.S.D.J.

 We hereby consent to the form and entry of this Order: 

Dated: October            , 2017 

 

			
	
                          
                                         
     
 Jack B. Blumenfeld

Maryellen Noreika
 MORRIS, NICHOLS, ARSHT

& TUNNELL LLP
 1201 North Market Street

P.O. Box 1347
 Wilmington, DE 19899

(302) 658-9200
  

George Pappas
 Jeffrey Lerner

Gary Rubman
 COVINGTON & BURLING LLP

One CityCenter
 850 10th St NW

Washington, DC 20001
 (202) 662-6000

 
 Attorneys for Omeros Corporation
	  	
                          
                                         
             
 Steven J. Fineman

Katharine Lester Mowery
 RICHARDS, LAYTON & FINGER, PA

One Rodney Square
 920 N. King Street

Wilmington, DE 19801
 (302) 651-7700

 
 Aziz Burgy

Brett M. Garrison
 David H. Silverstein

Francis H. Morrison , III
 Jeremy Lowe

Matthew S. Murphy
 Ricardo S. Camposanto

Seth I. Heller
 AXINN, VELTROP & HARKRIDER LLP

950 F St NW
 Washington, DC 20004

(202) 912-4700
  

Attorneys for Par Sterile Products, LLC and Par Pharmaceutical, Inc.

 EXHIBIT B 

REPORTING AND PAYMENT INFORMATION 
  

	1.	Gross Sales (units and dollars) 

  

	2.	Product Returns (dollars) 

  

	3.	Excise taxes, value added taxes, and duties (dollars) 

  

	4.	Trade, quantity, prompt pay and cash discounts (dollars) 

  

	5.	Allowances and credits (dollars) 

  

	6.	Rebates and chargebacks (dollars)EX-10.1

 Exhibit 10.1 

Execution Version 

THIRD AMENDMENT TO CREDIT AGREEMENT 

This THIRD AMENDMENT TO CREDIT AGREEMENT (this
“Third Amendment”), dated as of October 4, 2017 (the “Third Amendment Effective Date”), is among WildHorse Resource Development Corporation, a Delaware corporation (the “Borrower”); each of the
Guarantors party hereto (the “Guarantors” and collectively with the Borrower, the “Credit Parties”); each of the Lenders party hereto; and Wells Fargo Bank, National Association, as administrative agent for the
Lenders (in such capacity, together with its successors in such capacity, the “Administrative Agent”). 
 R E C I T A
L S: 
 A. The Borrower, the Administrative Agent and the Lenders are parties to that certain Credit Agreement dated
as of December 19, 2016 (as amended or otherwise modified from time to time to date pursuant to the terms thereof, the “Credit Agreement”), pursuant to which the Lenders have, subject to the terms and conditions set forth
therein, made certain credit available to and on behalf of the Borrower. 
 B. The Borrower has requested, among other
things, to amend certain terms of the Credit Agreement as set forth herein, including to increase the Aggregate Maximum Credit Amount to $2,000,000,000, to be effective as of the Third Amendment Effective Date. 

C. The Lenders have agreed to redetermine and increase the Borrowing Base to $875,000,000 effective as of the Third Amendment
Effective Date. 
 D. The Borrower has requested that ABN AMRO Capital USA LLC and PNC Bank, National Association (each, a
“New Lender” and, collectively, the “New Lenders”), become Lenders under the Credit Agreement with a Maximum Credit Amount and an Elected Commitment in the amount as shown on Annex I to the Credit Agreement (as
amended hereby). 
 E. Subject to and upon the terms and conditions set forth herein, the undersigned Lenders have agreed to
enter into this Third Amendment to amend certain provisions of the Credit Agreement as more specifically provided for herein. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

Section 1. Defined Terms. Each capitalized term which is defined in the Credit Agreement, but which is not defined
in this Third Amendment, shall have the meaning ascribed to such term in the Credit Agreement, as amended hereby. Unless otherwise indicated, all section references in this Third Amendment refer to the Credit Agreement, as amended hereby. 

Section 2. Amendments to Credit Agreement. In reliance on the representations, warranties, covenants and
agreements contained in this Third Amendment, and subject to the satisfaction of the conditions precedent set forth in Section 7 hereof, the Credit Agreement shall be amended effective as of the Third Amendment Effective Date in the
manner provided in this 

 
Section 2. 
  

	 	2.1	 Amendments to Section 1.02. 

 

	 	(a)	 The following definitions are hereby amended and restated as follows: 

“Aggregate Maximum Credit Amount” at any time shall equal the sum of the Maximum Credit Amounts, as the
same may be reduced or terminated pursuant to Section 2.06. As of the Third Amendment Effective Date (as defined in the Third Amendment), the Aggregate Maximum Credit Amount is $2,000,000,000. 

“Agreement” means this Credit Agreement, as amended by the First Amendment, the Second Amendment, the
Third Amendment and as the same may be further amended, modified, supplemented or restated from time to time. 

“Applicable Margin” means, for any day, with respect to any ABR Loan, LIBOR Market Index Loan or
Eurodollar Loan, or with respect to the Commitment Fee Rate, as the case may be, the rate per annum set forth in the Total Commitments Utilization Grid below based upon the Total Commitments Utilization Percentage then in effect: 

 

											
	 Total Commitments Utilization
Grid

	 Total Commitments Utilization Percentage
	  	<25%	    	325% <50%	    	350% <75%	    	375% <90%	    	390%
	 Eurodollar Loans
	  	2.000%	    	2.250%	    	2.500%	    	2.750%	    	3.000%
	 LIBOR Market Index Loans
	  	2.000%	    	2.250%	    	2.500%	    	2.750%	    	3.000%
	 ABR Loans
	  	1.000%	    	1.250%	    	1.500%	    	1.750%	    	2.000%
	 Commitment Fee Rate
	  	0.375%	    	0.375%	    	0.500%	    	0.500%	    	0.500%

 Each change in the Applicable Margin (whether as a result of a change in the Total Commitments
Utilization Percentage, as a result of an amendment of the definition of Applicable Margin, or otherwise) shall apply during the period commencing on the effective date of such change and ending on the date immediately preceding the effective date
of the next such change; provided that if at any time the Borrower fails to deliver a Reserve Report pursuant to Section 8.12 and such failure continues for more than 10 Business Days from the date when such Reserve Report is due,
then the “Applicable Margin” means the rate per annum set forth on the grid when the Total Commitments Utilization Percentage is at its highest level until such Reserve Report is delivered. 

“Consolidated EBITDAX” means, with respect to the Borrower and the Consolidated Restricted
Subsidiaries, for any period, Consolidated Net Income for such period plus, without duplication and to the extent reflected as a charge in the statement of such Consolidated Net Income for such period, the sum of (a) interest expense
(including realized and unrealized losses on interest rate derivative contracts); (b) income tax 

  
 Page 2 

 
expense; (c) depreciation, depletion and amortization expense; (d) impairment of goodwill and long-lived assets (including Oil and Gas Properties); (e) accretion of asset
retirement obligations; (f) unrealized losses on commodity derivative contracts; (g) realized losses upon the early termination or other monetization of commodity derivative contracts; (h) losses on sale of assets; (i) noncash
unit-based compensation expenses; (j) exploration costs; (k) brokers’ or finders’ fees, and other fees, in connection with acquisitions of Oil and Gas Properties permitted hereunder, and (l) fees and expenses expensed and
paid in cash in connection with the issuance of Debt and the issuance of Equity Interests, including fees and expenses expensed and paid in cash in connection with any registered offering of Equity Interests in the Borrower, including the Borrower
IPO; minus, without duplication and to the extent included in the statement of such Consolidated Net Income for such period, the sum of interest income (including realized and unrealized gains on interest rate derivative contracts); income
tax benefit; unrealized gains on commodity derivative contracts; realized gains upon the early termination or other monetization of commodity derivative contracts; and gains on sales of assets. For the purposes of calculating Consolidated EBITDAX
for any Rolling Period in connection with any determination of the financial ratio contained in Section 9.01(a), if during such Rolling Period, the Borrower or any Consolidated Restricted Subsidiary shall have made a Material Disposition
or Material Acquisition, the Consolidated EBITDAX for such Rolling Period shall be calculated after giving pro forma effect thereto as if such Material Disposition or Material Acquisition, as applicable, occurred on the first day of such Rolling
Period. For purposes of Consolidated EBITDAX for the Rolling Periods ending September 30, 2017, December 31, 2017 and March 31, 2018 in connection with any determination of the financial ratio contained in
Section 9.01(a), Consolidated EBITDAX shall be calculated as follows: (A) for the Rolling Period ending September 30, 2017, Consolidated EBITDAX shall be Consolidated EBITDAX for the Rolling Period ending on such date
multiplied by 4; (B) for the Rolling Period ending December 31, 2017, Consolidated EBITDAX shall be Consolidated EBITDAX for the Rolling Period ending on such date multiplied by 2; and (C) for the Rolling Period ending March 31,
2018, Consolidated EBITDAX shall be Consolidated EBITDAX for the Rolling Period ending on such date multiplied by 4/3. 

“Rolling Period” means (a) for the fiscal quarters ending on September 30,
2017, December 31, 2017 and March 31, 2018, the period commencing on July 1, 2017 and ending on the last day of such applicable fiscal quarter and (b) for the fiscal quarter ending on June 30, 2018, and for each fiscal
quarter thereafter, the period of four (4) consecutive fiscal quarters ending on the last day of such applicable fiscal quarter. 
  

	 	(c)	 The following definitions are hereby added where alphabetically appropriate to read as follows:

 “Applicable Letter of Credit Term” means (a) one year, in the case of a
Letter of Credit other than an RRC Letter of Credit, or (b) 18 months, in the case of an RRC Letter of Credit. 

“RRC Letter of Credit” means a Letter of Credit in respect of which the Railroad Commission of Texas
is the beneficiary. 

  
 Page 3 

 “Third Amendment” means that certain Third Amendment to
Credit Agreement, dated as of October 4, 2017, among the Borrower, the Guarantors, the Administrative Agent and the Lenders party thereto. 

“Third Amendment Effective Date” means October 4, 2017. 

 

	 	2.2	 Amendment to Section 2.08(c). Section 2.08(c) is hereby amended and restated in its entirety
to read as follows: 

 (c) Expiration Date. Each Letter of Credit shall expire at or
prior to the close of business on the earlier of (i) the date that is the Applicable Letter of Credit Term after the date of the issuance of such Letter of Credit (or, in the case of any renewal, which renewal may be provided for in the initial
Letter of Credit, or extension thereof, the Applicable Letter of Credit Term after such renewal or extension) and (ii) the date that is five Business Days prior to the Maturity Date. 

 

	 	2.3	 Replacement of Annex I. 

(a) Annex I to the Credit Agreement is hereby replaced in its entirety with Annex I attached hereto and
Annex I attached hereto shall be deemed to be attached as Annex I to the Credit Agreement. After giving effect to this Third Amendment and any Borrowings made on the Third Amendment Effective Date, (i) each Lender (including each
New Lender) who holds Loans in an aggregate amount less than its Applicable Percentage (after giving effect to this Third Amendment) of all Loans shall advance new Loans which shall be disbursed to the Administrative Agent and used to repay Loans
outstanding to each Lender who holds Loans in an aggregate amount greater than its Applicable Percentage of all Loans, (ii) each Lender’s participation in each Letter of Credit, if any, shall be automatically adjusted to equal its
Applicable Percentage (after giving effect to this Third Amendment) and (iii) such other adjustments shall be made as the Administrative Agent shall specify so that the Revolving Credit Exposure applicable to each Lender equals its Applicable
Percentage (after giving effect to this Third Amendment) of the aggregate Revolving Credit Exposure of all Lenders. 
 (b)
The Administrative Agent, the Issuing Banks and the Borrower hereby consent to the reallocations and payments pursuant to this Section 2.3 and waive the delivery of an Assignment and Assumption and any other condition (other than the
delivery by each New Lender of an Administrative Questionnaire) to the effectiveness of the foregoing reallocations and payments. The Administrative Agent hereby consents to a one-time waiver of the $3,500 processing and recordation fee that would
otherwise be payable pursuant to Section 12.04(b)(ii)(C) if the reallocations and payments provided for herein were structured as assignments by Lenders receiving such payments to Lenders (including New Lenders) making such payments. Each
existing Lender waives any break-funding payments otherwise payable under Section 5.02 in connection with the repayment of any Loans in accordance with this Section 2.3. 

Section 3. Omnibus Amendment to Loan Documents. All references in the Loan Documents to “U.S. Bank” that
are not followed by the words “National Association” have been 

  
 Page 4 

 
at all times intended to refer to, and are hereby amended to read, “U.S. Bank National Association”. 

Section 4. Aggregate Elected Commitment Amounts. Pursuant to Section 2.06(c), the Aggregate Elected
Commitment Amounts shall be increased to $875,000,000, effective as of the Third Amendment Effective Date, and the Borrower and the Lenders agree and acknowledge that the Elected Commitment of each Lender shall be as more particularly set forth on
Annex I attached hereto and that each New Lender shall be deemed to have executed and delivered Exhibit H attached to the Credit Agreement pursuant to the terms thereof. 

Section 5. Borrowing Base Redetermination. Pursuant to Section 2.07, the Administrative Agent and the Lenders
agree that for the period from and including the Third Amendment Effective Date to but excluding the next Redetermination Date, the amount of the Borrowing Base shall be equal to $875,000,000. Notwithstanding the foregoing, the Borrowing Base may be
subject to further adjustments from time to time pursuant to Section 2.07(e), Section 2.07(f) or Section 8.12(c). For the avoidance of doubt, the redetermination herein shall constitute the October 1, 2017 Scheduled
Redetermination and the next Scheduled Redetermination shall be the April 1, 2018 Scheduled Redetermination. 

Section 6. New Lenders. Each New Lender hereby joins in, becomes a party to, and agrees to comply with and be
bound by the terms and conditions of the Credit Agreement as amended hereby as a Lender thereunder and under each and every other Loan Document to which any Lender is required to be bound by the Credit Agreement as amended hereby, to the same extent
as if such New Lender were an original signatory thereto. Each New Lender hereby appoints and authorizes the Administrative Agent to take such action as agent on its behalf and to exercise such powers and discretion under the Credit Agreement as
amended hereby as are delegated to the Administrative Agent by the terms thereof, together with such powers and discretion as are reasonably incidental thereto. Each New Lender represents and warrants that (a) it has full power and authority,
and has taken all action necessary, to execute and deliver this Third Amendment, to consummate the transactions contemplated hereby and to become a party to, and a Lender under, the Credit Agreement as amended hereby, (b) it has received a copy
of the Credit Agreement and copies of the most recent financial statements delivered pursuant to Section 8.01, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this
Third Amendment and to become a Lender on the basis of which it has made such analysis and decision independently and without reliance on the Administrative Agent or any other Lender, and (c) from and after the Third Amendment Effective Date,
it shall be a party to and be bound by the provisions of the Credit Agreement as amended hereby and the other Loan Documents and have the rights and obligations of a Lender thereunder. 

Section 7. Conditions Precedent. The effectiveness of this Third Amendment is subject to the following: 

7.1 The Administrative Agent shall have received counterparts (in such number as may be requested by the Administrative Agent)
of this Third Amendment from the Borrower, each Guarantor and each Lender (including each New Lender). 
 7.2 The
Administrative Agent shall have received an Administrative Questionnaire 

  
 Page 5 

 
from each New Lender. 
 7.3 The Administrative Agent shall have
received from the relevant Loan Parties duly executed and notarized mortgages and/or mortgage supplements or amendments in form and substance reasonably satisfactory to the Administrative Agent so that, after giving effect to the recording of such
mortgages, mortgage supplements and/or amendments, the Administrative Agent shall be reasonably satisfied that it has first priority, perfected Liens (subject only to Excepted Liens identified in clauses (a) to (d) and (f) of the
definition thereof, but subject to the provisos at the end of such definition) on at least 85% of the total value (as determined by the Administrative Agent based on the present value of the Proved Reserves attributable thereto using a 9% discount
rate) of the Oil and Gas Properties evaluated in the Reserve Report most recently delivered pursuant to Section 8.12(a), including any amendments necessary to reflect the Aggregate Maximum Credit Amount (as amended by this Third Amendment).

 7.4 The Administrative Agent shall have received from the Borrower title information setting forth the status of title to
at least 85% of the total value (as determined by the Administrative Agent based on the present value of the Proved Reserves attributable thereto using a 9% discount rate) of the Oil and Gas Properties evaluated in the Reserve Report most recently
delivered pursuant to Section 8.12(a). 
 7.5 No Default or Borrowing Base Deficiency shall have occurred and be
continuing as of the date hereof after giving effect to the terms of this Third Amendment. 
 7.6 The Administrative Agent
shall have received all fees and other amounts due and payable to the Administrative Agent or any Lenders in connection with this Third Amendment. 

7.7 The Administrative Agent shall have received duly executed Notes payable to each Lender requesting a Note in a principal
amount equal to its Maximum Credit Amount (as amended by this Third Amendment) dated as of the date hereof. 
 7.8 The
Administrative Agent shall have received such other documents as the Administrative Agent or its special counsel may reasonably require. 

The Administrative Agent is hereby authorized and directed to declare this Third Amendment to be effective when it has received documents
confirming or certifying, to the satisfaction of the Administrative Agent, compliance with the conditions set forth in this Section 7 or the waiver of such conditions as permitted hereby. Such declaration shall be final, conclusive and
binding upon all parties to the Credit Agreement for all purposes. 
 Section 8. Return of Promissory Notes.
Promptly upon receipt of any replacement Note under Section 7.7 hereof, each Lender shall return to the Administrative Agent (for delivery to the Borrower for cancellation) any other Note in such Lender’s possession that was
previously delivered to such Lender under the Credit Agreement. 
 Section 9. Miscellaneous. 

9.1 Confirmation and Effect. The provisions of the Credit Agreement (as amended by this Third Amendment) shall remain
in full force and effect in accordance with its terms 

  
 Page 6 

 
following the Third Amendment Effective Date, and this Third Amendment shall not constitute a waiver of any provision of the Credit Agreement or any other Loan Document, except as expressly
provided for herein. Each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof’, “herein”, or words of like import shall mean and be a reference to the Credit Agreement as amended
hereby, and each reference to the Credit Agreement in any other document, instrument or agreement executed and/or delivered in connection with the Credit Agreement shall mean and be a reference to the Credit Agreement as amended hereby. 

9.2 No Waiver. Neither the execution by the Administrative Agent or the Lenders of this Third Amendment, nor any other
act or omission by the Administrative Agent or the Lenders or their officers in connection herewith, shall be deemed a waiver by the Administrative Agent or the Lenders of any Defaults or Events of Default which may exist, which may have occurred
prior to the date of the effectiveness of this Third Amendment or which may occur in the future under the Credit Agreement and/or the other Loan Documents. Similarly, nothing contained in this Third Amendment shall directly or indirectly in any way
whatsoever either: (a) impair, prejudice or otherwise adversely affect the Administrative Agent’s or the Lenders’ right at any time to exercise any right, privilege or remedy in connection with the Loan Documents with respect to any
Default or Event of Default, (b) except as expressly provided herein, amend or alter any provision of the Credit Agreement, the other Loan Documents, or any other contract or instrument, or (c) constitute any course of dealing or other
basis for altering any obligation of the Borrower or any right, privilege or remedy of the Administrative Agent or the Lenders under the Credit Agreement, the other Loan Documents, or any other contract or instrument. 

9.3 Ratification and Affirmation of Credit Parties. Each Credit Party hereby expressly (i) acknowledges the terms
of this Third Amendment, (ii) ratifies and affirms its obligations under the Guaranty Agreement, the Security Agreement and the other Loan Documents to which it is a party, (iii) acknowledges, renews and extends its continued liability
under the Guaranty Agreement, the Security Agreement and the other Loan Documents to which it is a party, (iv) agrees that its guarantee under the Guaranty Agreement and its pledge of collateral under the Security Agreement and any of its
obligations under the other Loan Documents to which it is a party remain in full force and effect with respect to the Indebtedness as amended hereby, (v) represents and warrants to the Lenders and the Administrative Agent that each
representation and warranty of such Person contained in the Credit Agreement (as amended by this Third Amendment) and the other Loan Documents to which it is a party is true and correct in all material respects as of the date hereof and after giving
effect to this Third Amendment except (A) to the extent any such representations and warranties are expressly limited to an earlier date, in which case such representations and warranties shall continue to be true and correct as of such
specified earlier date, and (B) to the extent that any such representation and warranty is expressly qualified by reference to materiality, a Material Adverse Effect or similar qualification, in which case such representations and warranties
shall be true and correct in all respects, (vi) represents and warrants to the Lenders and the Administrative Agent that the execution, delivery and performance by such Person of this Third Amendment are within such Person’s corporate,
limited partnership or limited liability company powers (as applicable), have been duly authorized by all necessary action and that this Third Amendment constitutes the valid and binding obligation of such Person enforceable in accordance with its
terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of 

  
 Page 7 

 
whether considered in a proceeding in equity or at law, and (vii) represents and warrants to the Lenders and the Administrative Agent that, after giving effect to this Third Amendment, no
Default or Event of Default exists. 
 9.4 Counterparts. This Third Amendment may be executed in counterparts (and by
different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Third Amendment
by facsimile or other electronic transmission (e.g., .pdf) shall be effective as delivery of a manually executed counterpart of this Third Amendment. 

9.5 No Oral Agreement. THIS WRITTEN THIRD AMENDMENT,
THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS EXECUTED IN CONNECTION
HEREWITH AND THEREWITH REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES HERETO
AND THERETO AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR,
CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO
UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES. 

9.6 Governing Law. THIS THIRD AMENDMENT SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE
STATE OF NEW YORK. 
 9.7 Payment of Expenses. The
Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable and documented out-of-pocket costs and expenses incurred in connection with this Third Amendment in accordance with Section 12.03. 

9.8 Severability. Any provision of this Third Amendment or any other Loan Document held to be invalid, illegal or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions hereof or
thereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction. 

9.9 Successors and Assigns. This Third Amendment shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns (in each case, as permitted by Section 12.04). 
 9.10 Loan
Document. This Third Amendment shall constitute a “Loan Document” under and as defined in Section 1.02. 
 [Signature
Pages Follow] 

  
 Page 8 

 The parties hereto have caused this Third Amendment to be duly executed as of the
day and year first above written. 
 BORROWER: 

 

			
	WILDHORSE RESOURCE DEVELOPMENT CORPORATION, a Delaware corporation
		
	 By:
	 	 /s/ Andrew J. Cozby

	 Name:
	 	 Andrew J. Cozby

	 Title:
	 	 Executive Vice President and Chief

		 	 Financial Officer

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 GUARANTORS: 

 

			
	WILDHORSE RESOURCES II, LLC, a Delaware limited liability company
	 By: WildHorse Resource Development Corporation, its sole member

	ESQUISTO RESOURCES II, LLC, a Texas limited liability company
	 By: WildHorse Resource Development Corporation, its sole member

	WHE ACQCO., LLC, a Delaware limited liability company
	 By: WildHorse Resource Development Corporation, its sole member

	WHR EAGLE FORD LLC, a Delaware limited liability company
	 By: WildHorse Resource Development Corporation, its sole member

		
	By:	 	 /s/ Andrew J. Cozby

	Name:	 	Andrew J. Cozby
	Title:	 	Executive Vice President and Chief
		 	Financial Officer
	
	WILDHORSE RESOURCES MANAGEMENT COMPANY, LLC, a Delaware limited liability company
	 By: WildHorse Resources II, LLC, its sole member,

	 By: WildHorse Resource Development Corporation, its sole member

	OAKFIELD ENERGY LLC, a Delaware limited liability company
	 By: WildHorse Resources II, LLC, its sole member,

	 By: WildHorse Resource Development Corporation, its sole member

		
	By:	 	 /s/ Andrew J. Cozby

	Name:	 	Andrew J. Cozby
	Title:	 	Executive Vice President and Chief
		 	Financial Officer

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	PETROMAX E&P BURLESON, LLC, a Texas limited liability company
	 By: Esquisto Resources II, LLC, its sole member,

	 By: WildHorse Resource Development Corporation, its sole member

		
	By:	 	 /s/ Andrew J. Cozby

	Name:	 	Andrew J. Cozby
	Title:	 	Executive Vice President and Chief
		 	Financial Officer
	
	BURLESON WATER RESOURCES, LLC, a Texas limited liability company
	 By: Esquisto Resources II, LLC, its sole member,

	 By: WildHorse Resource Development Corporation, its sole member

		
	By:	 	 /s/ Andrew J. Cozby

	Name:	 	Andrew J. Cozby
	Title:	 	Executive Vice President and Chief
		 	Financial Officer

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 ADMINISTRATIVE AGENT AND LENDERS: 

 

			
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent and a Lender
		
	 By:
	 	 /s/ Russell Otts

	 Name:
	 	 Russell Otts

	 Title:
	 	 Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	BMO HARRIS BANK N.A., as a Lender
		
	 By:
	 	 /s/ Gumaro Tijerina

	 Name:
	 	 Gumaro Tijerina

	 Title:
	 	 Managing Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	BANK OF AMERICA, N.A., as a Lender
		
	 By:
	 	 /s/ Raza Jafferi

	 Name:
	 	 Raza Jafferi

	 Title:
	 	 Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	 BARCLAYS BANK PLC, as a Lender

		
	 By:
	 	 /s/ Vanessa A. Kurbatskly

	 Name:
	 	 Vanessa A. Kurbatskly

	 Title:
	 	 Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	CITIBANK, N.A., as a Lender
		
	 By:
	 	 /s/ Phil Ballard

	 Name:
	 	 Phil Ballard

	 Title:
	 	 Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	COMERICA BANK, as a Lender
		
	 By:
	 	 /s/ William B. Robinson

	 Name:
	 	 William B. Robinson

	 Title:
	 	 Senior Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	ING CAPITAL LLC, as a Lender
		
	 By:
	 	 /s/ Josh Strong

	 Name:
	 	 Josh Strong

	 Title:
	 	 Director

		
	 By:
	 	 /s/ Julie Bieser

	 Name:
	 	 Julie Bieser

	 Title:
	 	 Managing Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	BOKF, N.A. DBA BANK OF TEXAS, as a Lender
		
	 By:
	 	 /s/ Martin W. Wilson

	 Name:
	 	 Martin W. Wilson

	 Title:
	 	 SVP-Energy Lending

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	 CAPITAL ONE NATIONAL ASSOCIATION, 

as a Lender

		
	 By:
	 	 /s/ Michael Higgins

	 Name:
	 	 Michael Higgins

	 Title:
	 	 Senior Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	JPMORGAN CHASE BANK, N.A., as a Lender
		
	 By:
	 	 /s/ Jo Linda Papadakis

	 Name:
	 	 Jo Linda Papadakis

	 Title:
	 	 Authorized Officer

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	ASSOCIATED BANK, N.A., as a Lender
		
	 By:
	 	 /s/ Kyle Lewis

	 Name:
	 	 Kyle Lewis

	 Title:
	 	 Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	COMPASS BANK, as a Lender
		
	 By:
	 	 /s/ Kathleen J. Bowen

	 Name:
	 	 Kathleen J. Bowen

	 Title:
	 	 Managing Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	CANADIAN IMPERIAL BANK OF COMMERCE, NEW YORK BRANCH, as a Lender
		
	 By:
	 	 /s/ Richard Antl

	 Name:
	 	 Richard Antl

	 Title:
	 	 Authorized Signatory

		
	 By:
	 	 /s/ William M. Reid

	 Name:
	 	 William M. Reid

	 Title:
	 	 Authorized Signatory

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	FIFTH THIRD BANK, as a Lender
		
	 By:
	 	 /s/ Justin Bellamy

	 Name:
	 	 Justin Bellamy

	 Title:
	 	 Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	U.S. BANK NATIONAL ASSOCIATION, as a Lender
		
	 By:
	 	 /s/ Heather Han

	 Name:
	 	 Heather Han

	 Title:
	 	 Senior Vice President

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	ABN AMRO CAPITAL USA LLC, as a New Lender
		
	 By:
	 	 /s/ Darrell Holley

	 Name:
	 	 Darrell Holley

	 Title:
	 	 Managing Director

		
	 By:
	 	 /s/ Elizabeth Johnson

	 Name:
	 	 Elizabeth Johnson

	 Title:
	 	 Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 
			
	PNC BANK, NATIONAL ASSOCIATION, as a New Lender
		
	 By:
	 	 /s/ Sandra Aultman

	 Name:
	 	 Sandra Aultman

	 Title:
	 	 Managing Director

 SIGNATURE PAGE TO THIRD
AMENDMENT TO CREDIT AGREEMENT 
 WILDHORSE
RESOURCE DEVELOPMENT CORPORATION 

 ANNEX I 

LIST OF MAXIMUM CREDIT AMOUNTS AND ELECTED COMMITMENTS 
  

							
	 Name of Lender
	    	Applicable
Percentage	    	Maximum Credit
Amount	    	Elected
Commitment
	 Wells Fargo Bank, National Association
	    	8.0571%	    	$161,142,857.17	    	$70,500,000.00
	 BMO Harris Bank N.A.
	    	7.7714%	    	$155,428,571.45	    	$68,000,000.00
	 Bank of America, N.A.
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 Barclays Bank PLC
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 Citibank, N.A.
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 Comerica Bank
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 ING Capital LLC
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 JPMorgan Chase Bank, N.A.
	    	6.6286%	    	$132,571,428.57	    	$58,000,000.00
	 ABN AMRO Capital USA LLC
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 BOKF, N. A. DBA Bank of Texas
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 Canadian Imperial Bank of Commerce, New York Branch
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 Capital One National Association
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 Compass Bank
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 Fifth Third Bank
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 PNC Bank, National Association
	    	5.4857%	    	$109,714,285.71	    	$48,000,000.00
	 U.S. Bank National Association
	    	3.1429%	    	$62,857,142.85	    	$27,500,000.00
	 Associated Bank, N.A.
	    	2.8571%	    	$57,142,857.14	    	$25,000,000.00
	 TOTAL
	    	100.00000000%	    	$2,000,000,000.00	    	$875,000,000.00

 ANNEX I

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]